Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Accumulated Expenses (2016 - 2025)

Anaptysbio's Accumulated Expenses history spans 10 years, with the latest figure at $11.1 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 31.31% year-over-year to $11.1 million; the TTM value through Dec 2025 reached $11.1 million, up 31.31%, while the annual FY2025 figure was $11.1 million, 31.31% up from the prior year.
  • Accumulated Expenses reached $11.1 million in Q4 2025 per ANAB's latest filing, down from $33.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $38.4 million in Q3 2024 to a low of $8.4 million in Q4 2024.
  • Average Accumulated Expenses over 5 years is $23.5 million, with a median of $23.8 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: soared 110.39% in 2023, then plummeted 72.72% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $12.9 million in 2021, then surged by 68.31% to $21.6 million in 2022, then soared by 43.15% to $31.0 million in 2023, then tumbled by 72.72% to $8.4 million in 2024, then surged by 31.31% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Accumulated Expenses are $11.1 million (Q4 2025), $33.2 million (Q3 2025), and $30.2 million (Q2 2025).